Jury Finds in Favor of Competitive Technologies On Homocysteine Patent Infringement Case

Fairfield, Connecticut, UNITED STATES

FAIRFIELD, Conn., Nov. 21, 2001 (PRIMEZONE) -- Competitive Technologies, Inc. (AMEX:CTT) announced today that a jury in a trial in the U.S. District Court for the District of Colorado found in favor of CTT and its licensee Metabolite Laboratories, Inc.

The jury confirmed the validity of patent usage by Laboratory Corporation of America Holdings (LabCorp), that LabCorp had contributed to and induced infringement and that the infringement was willful. CTT and its client the University of Colorado were awarded initially $1.0 million for infringement and expect the court to address in the next two weeks issues of interest on delayed payments, legal cost, and punitive damages, as well as continuing royalties.. CTT will retain approximately $400,000 of the initial award.

On May 4, 1999, Metabolite Laboratories, Inc. (MLI) and CTT (collectively plaintiffs) filed a complaint and jury demand against LabCorp in the United States District Court for the District of Colorado. The complaint alleged, among other things, that LabCorp owed plaintiffs royalties for homocysteine assays performed beginning in the summer of 1998 that fell within the claims of a patent owned by CTT. CTT licensed the patent non-exclusively to MLI and MLI sublicensed it to LabCorp. Plaintiffs claimed LabCorp's actions constituted breach of contract and patent infringement. The claim sought an injunction ordering LabCorp to perform all its obligations under its agreement, to cure past breaches, to provide an accounting of wrongfully withheld royalties and to refrain from infringing the patent. Plaintiffs also sought unspecified money and exemplary damages and attorneys' fees, among other things. In earlier released financial reports, CTT had recorded known legal expenses it incurred in this suit but had recorded no revenue for the withheld royalties.

Homocysteine has been shown to be a highly sensitive indicator of B12 and/or folate deficiency. Physicians, using the homocysteine assay as a diagnostic test, are reporting that elevated levels of homocysteine resulting from vitamin B12 and folate deficiency have been associated with vascular disease, Alzheimer's, rheumatoid arthritis and other diseases.

CTT has licensed the patent covering performance of assays for homocysteine to several clinical laboratories. The patent is derived from discoveries made by CTT's clients Drs. Robert Allen and Sally Stabler from the University of Colorado and the late Dr. John Lindenbaum from Columbia University.

CTT earns royalties on homocysteine assays performed. Approximately 20 million Americans -- one cardiovascular patient in every three -- have elevated homocysteine levels indicative of a deficiency in vitamin B12 and folate. Currently less than 1 million homocysteine assays are performed each year.

"CTT is gratified that this matter has been brought to closure," said Frank R. McPike, Jr., President and CEO of CTT. "We are especially pleased that the jury has found in favor of the University and the inventors in this litigation and also found that the patent was valid. This is an important assay that physicians use as a diagnostic test to determine elevated homocysteine levels and related vitamin deficiencies in patients with vascular disease, pregnancy complications, and dementia, including Alzheimer's and other diseases.

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in identifying, developing and commercializing innovative life sciences, physical sciences and digital technologies. Competitive Technologies' specialized expertise and experiences make it a valuable partner for inventors, companies and universities of all sizes. CTT has been responsible for closing hundreds of licensing agreements. CTT clients and licensees include: Sony, Matsushita Electric Industrial, the University of Arizona, the University of Colorado, the University of Illinois, Digital Ink, Inc., NTRU Cryptosystems, Inc., Palatin Technologies, Inc. and Ribozyme Pharmaceuticals, Inc. Competitive Technologies, Inc. is based in Fairfield, Connecticut and has affiliates in Osaka, Japan and London, England.

Statements about the Company's future expectations, including development and regulatory plans, and all other statements in this document other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws and are not guarantees of future performance. These statements involve risks and uncertainties related to market acceptance of and competition for the Company's licensed technologies and other risks and uncertainties inherent in CTT's business, including those set forth in Item 1 of the Company's most recent Form 10-K and other factors that may be described in CTT's filings with the SEC, and are subject to change at any time. The Company's actual results could differ materially from these forward-looking statements. The Company undertakes no obligation to update publicly any forward-looking statement.


Contact Data